SNORA39: A Potential Drug Target and Biomarker for the Treatment of Chronic Obstructive Pulmonary Disease

Target Name: SNORA71E

NCBI ID: G677821

SNORA71E

Other Name(s): SNORA39 | ACA39 | Small nucleolar RNA, H/ACA box 71E | small nucleolar RNA, H/ACA box 71E

SNORA39: A Potential Drug Target and Biomarker for the Treatment of Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide, leading to significant morbidity and mortality. Chronic obstructive pulmonary disease is characterized by a persistent obstruction of airflow in the lungs, leading to decreased lung expansion and reduced gas exchange. COPD can be caused by a variety of factors, including smoking, genetics, and exposure to environmental irritants.

SNORA39 is a protein that is expressed in the airways of individuals with COPD. It is a key regulator of cell signaling and has been shown to play a role in the development and progression of COPD. SNORA39 has also been shown to be a potential drug target for the treatment of COPD.

The exact mechanism by which SNORA39 contributes to COPD is not yet fully understood, but it is thought to influence the regulation of surfactant production and cell signaling. Surfactants are a type of protein that helps to reduce surface tension in the airways, making it easier for air to flow in and out of the lungs. The production of surfactants is regulated by SNORA39, and studies have shown that SNORA39 knockdown mice have increased airway resistance and reduced surfactant production, leading to improved lung function and reduced COPD-like symptoms.

In addition to its role in surfactant production, SNORA39 has also been shown to regulate the growth and differentiation of airway epithelial cells. airway epithelial cells are the cells that line the airways of the lungs and play a key role in regulating airway surface area and permeability. Studies have shown that SNORA39 can cause airway epithelial cells to differentiate into different cell types, including stem cells and progenitor cells, and that this process is dependent on SNORA39.

Another function of SNORA39 is its role in cell signaling. The cAMP/Cas system is a well-established signaling pathway that is involved in many cellular processes, including cell growth, differentiation, and inflammation. Studies have shown that SNORA39 can regulate the activity of the cAMP/Cas system and that this regulation is critical for the development and progression of COPD.

In conclusion, SNORA39 is a protein that is expressed in the airways of individuals with COPD and has been shown to play a role in the development and progression of COPD. The exact mechanism by which SNORA39 contributes to COPD is not yet fully understood, but it is thought to influence the regulation of surfactant production, cell signaling, and cell differentiation. These findings suggest that SNORA39 may be a potential drug target for the treatment of COPD. Further research is needed to fully understand the role of SNORA39 in COPD and to develop effective treatments.

Protein Name: Small Nucleolar RNA, H/ACA Box 71E

The "SNORA71E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA71E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets